DOCSLIB.ORG

Realizing the Potential of Focus

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Realizing the Potential of Focus Bedoyecta Acanya CeraVe Diastat Kinerase Atralin Cesamet Migranal Realizing the Potential of Focus Corporate Headquarters: One Enterprise, Aliso Viejo, CA 92656 www.valeant.com Valeant Pharmaceuticals 2008 Annual Report BIV51347_cvr_spd13.indd 1 3/24/09 10:44:23 PM Company Overview 2008 REVENUE BREAKOUT Corporate Information Corporate Headquarters Valeant Pharmaceuticals International (NYSE:VRX) is a multi- Alliance Revenue One Enterprise national specialty pharmaceutical company that develops and Product Sales BOARD OF DIRECTORS Aliso Viejo, CA 92656 markets prescription and nonprescription pharmaceutical products (949) 461-6000 that make a meaningful diff erence in patients’ lives. Valeant is J. Michael Pearson www.valeant.com focused on the neurology and dermatology therapeutic areas Chairman, Valeant Pharmaceuticals International primarily in the United States, Canada, Mexico, Brazil, Central Chief Executive Offi cer, Valeant Pharmaceuticals International Principal Transfer Agent & Registrar For Stockholders questions regarding lost stock certifi cates, address Europe and Australia. Robert A. Ingram changes and changes in ownership or names in which shares are Lead Director, Valeant Pharmaceuticals International held, direct inquiries to: Th roughout 2008, Valeant’s new management team simplifi ed Vice Chairman, Pharmaceuticals of GlaxoSmithKline and refocused its business strategy to concentrate on the company’s Committees: Compensation, Corporate Governance/Nominating American Stock Transfer and Trust Company strengths in the neurology and dermatology therapeutic areas. 6201 15th Avenue Valeant will maximize its pipeline through strategic partnering Richard H. Koppes Brooklyn, NY 11219 to optimize its research and development assets and strengthen Of Counsel, Jones Day (800) 937-5449 ongoing internal development capabilities. During the year, Committees: Compensation, Corporate Governance/Nominating the company made signifi cant strides by divesting its licensing Independent Auditors rights in Argentina, the Asia Pacifi c region, Western and Eastern Lawrence N. Kugelman PricewaterhouseCoopers LLP Europe, the Middle East and Africa. Additionally, Valeant Director, Coventry Healthcare Orange County, California signed an exclusive worldwide partnership agreement with CONSOLIDATED REVENUE Committees: Compensation, Finance and Audit GlaxoSmithKline for retigabine, its Phase III compound Alliance Revenue Annual Meeting for the treatment of partial onset seizures in adult pa- Anders Lönner Th e Annual Meeting of Stockholders will be held at 9:00 a.m. Product Sales tients with refractory epilepsy. Valeant also entered into a Group President and Chief Executive Offi cer, Meda AB EDT, May 12, 2009 at the Hilton Short Hills Hotel: joint venture agreement with Meda AB to strengthen its Th eo Melas-Kyriazi 41 John F. Kennedy Parkway presence in Australia, Canada and Mexico through $604 $603 development, marketing and commercialization of certain $546 $593 Chief Financial Offi cer, Levitronix LLC Short Hills, NJ 07078 current and future products. During 2008, Valeant acquired Committees: Corporate Governance/Nominating (Chairman), All stockholders are welcome. Coria Laboratories, Ltd., DermaTech Pty Ltd, and Dow Finance and Audit Pharmaceutical Sciences, Inc., and expanded its dermatology $431 Investor and Media Relations product portfolio and pipeline with prescription and OTC products. G. Mason Morfi t You may request a copy of documents at no cost by contacting: Partner, ValueAct Capital Laurie W. Little Vice President, Investor Relations Based in Orange County, California, Valeant employs approximately Committees: Compensation (Chairman), Corporate Governance/Nominating (949) 461-6002 2,300 people worldwide. For more information about Valeant $92 $76 $81 $86 $64 [email protected] Pharmaceuticals International, please visit our corporate website Norma A. Provencio Email updates are also available through the Investor Relations page at www.valeant.com. at Valeant’s website. 2004 2005 2006 2007 2008 President and Owner, Provencio Advisory Services Committees: Finance and Audit (Chairperson), Compensation SPECIALTY PHARMACEUTICALS Stock Exchange AND BRANDED GENERICS DIVERSIFIED PRODUCT PORTFOLIO MANAGEMENT TEAM New York Stock Exchange NYSE Trading Symbol Specialty Pharmaceuticals J. Michael Pearson Common Stock: VRX Revenues as of 12/31/08 Chairman and Chief Executive Offi cer 2008 2007 % U.S. 36 Peter J. Blott Dermatology $ 91,708 $ 92,751 Branded Generics Executive Vice President, Chief Financial Offi cer Neurology & Other 127,641 131,968 Total U.S. 219,349 224,719 % Dr. Bhaskar Chaudhuri President, Valeant Pharmaceuticals International Canada 56,988 51,952 55 Specialty Pharmaceuticals Australia 21,602 19,467 Rajiv De Silva Divested Business 5,784 30,544 % Chief Operating Offi cer of Specialty Pharmaceuticals 9 Over-the-Counter Total Specialty Pharmaceuticals 303,723 326,682 Elisa Karlson Executive Vice President and Chief Administrative Offi cer Branded Generics Branded Generics - Latin America 136,638 151,299 Richard K. Masterson Branded Generics - Europe 152,804 125,070 Executive Vice President, Commercial Development 593,165 603,051 Steve T. Min Executive Vice President, General Counsel and Corporate Secretary Total, net of divested businesses $587,381 $572,507 BIV51347_cvr_spd_23.indd 2 3/30/09 8:43:13 AM Valeant Pharmaceuticals 2008 Annual Report Throughout 2008, Valeant’s new management team simplifi ed its business strategy to focus on the company’s strengths in the neurology and dermatology therapeutic areas. Valeant will maximize its pipeline through strategic partnering to optimize its research and development assets and strengthen ongoing internal development capabilities. Forward-looking Statements: Th is annual report contains forward-looking statements, including, but not limited to, statements regarding the growth and profi tability of the company, the eff ects of restructuring eff orts, regulatory submissions with respect to and the approvability of product candidates, the potential for taribavirin in the treatment of hepatitis C, clinical trial results, securities repurchases, future cash fl ows and guidance with respect to expected earnings. Th ese statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to diff er materially from those described in the forward-looking statements. Th ese risks and uncertainties include, but are not limited to, risks and uncertainties related to the company’s ability to realize the benefi ts of its strategic restructuring plan, the fact that market conditions and other factors that may infl uence the company’s determination as to whether and when to repurchase its securities, the ability of the company to complete the programs in compliance with applicable requirements, the clinical development of new products, regulatory approval processes, the fact that interim results from a Phase IIb clinical trial are not necessarily predictive of the entire Phase IIb trial or a Phase III trial, and other risks and uncertainties discussed in the company’s annual report on Form 10-K for the year ended December 31, 2008 and other fi lings with the SEC. Valeant wishes to caution the reader that these factors are among the factors that could cause actual results to diff er materially from the expectations described in the forward-looking statements. Valeant also cautions the reader that undue reliance should not be placed on any of the forward-looking state- ments, which speak only as of the date of this annual report. Th e company undertakes no obligation to update any of these forward-looking statements to refl ect events or circumstances after the date of this annual report or to refl ect actual outcomes. Valeant Pharmaceuticals 2008 Annual Report To our stockholders, 2008’S SIX STRATEGIC INITIATIVES In March 2008, we established six key milestone initiatives that we focused on and diligently strived to achieve by the end of the 2008 marked a major turning point for Valeant as we signifi cantly year. I am proud to say that we completed most of these initiatives restructured and right-sized our business, forged new partnerships, and expect to put the fi nal touches on the remaining initiative in added products to our portfolio and pipeline, and divested com- 2009. plex operations. Th e net result is a more robust pharmaceutical company that is strategically positioned for future growth. 1. SELL/IPO EUROPE We announced our plans to divest the majority of our European When I joined Valeant as Chairman and CEO in February of operations in July and successfully closed the transaction in Sep- 2008, the company looked much diff erent than it does today. We tember for $428 million in cash from Meda AB. As for the pos- were in many countries, operating diff erent businesses, and selling sible IPO or sale of our remaining Central European operations, a wide variety of products. Since my arrival, we replaced some of we are no longer considering a near-term IPO due to current mar- our assets with ones that are more suitable to our new business ket conditions. Although an IPO or a sale remains a possibility in strategy. We set about restructuring both our business operations the future, our current plans are to keep these operations as part of and our corporate culture into a lean, cost-eff ective, decentral- the Valeant business as it continues to deliver double digit growth ized organization. We partnered retigabine,
Load more

Recommended publications
  • CRPT-113Hrpt565-Pt2.Pdf
    113TH CONGRESS REPT. 113–565 " ! 2d Session HOUSE OF REPRESENTATIVES Part 2 IMPROVING REGULATORY TRANSPARENCY FOR NEW MEDICAL THERAPIES ACT SEPTEMBER 19, 2014.—Committed to the Committee of the Whole House on the State of the Union and ordered to be printed Mr. GOODLATTE, from the Committee on the Judiciary, submitted the following R E P O R T [To accompany H.R. 4299] [Including cost estimate of the Congressional Budget Office] The Committee on the Judiciary, to whom was referred the bill (H.R. 4299) to amend the Controlled Substances Act with respect to drug scheduling recommendations by the Secretary of Health and Human Services, and with respect to registration of manufac- turers and distributors seeking to conduct clinical testing, having considered the same, report favorably thereon with an amendment and recommend that the bill as amended do pass. CONTENTS Page The Amendment ...................................................................................................... 1 Purpose and Summary ............................................................................................ 2 Background and Need for the Legislation ............................................................. 2 Hearings ................................................................................................................... 3 Committee Consideration ........................................................................................ 3 Committee Votes .....................................................................................................
    [Show full text]
  • Guidance for Industry Postmarketing Safety Reporting for Human Drug and Biological Products Including Vaccines
    Guidance for Industry Postmarketing Safety Reporting for Human Drug and Biological Products Including Vaccines DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the Federal Register of the notice announcing the availability of the draft guidance. Submit comments to Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20857. All comments should be identified with the docket number listed in the notice of availability that publishes in the Federal Register. For questions on the content of the draft document contact (CDER) Min Chen, 301-827- 3169 (phone); 301-827-5190 (fax), or (CBER) Miles Braun, 301-827-3974 (phone); 301- 827-3529 (fax). U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) March 2001 G:\4177dft.doc Guidance for Industry Postmarketing Safety Reporting for Human Drug and Biological Products Including Vaccines Additional copies are available from: Drug Information Branch (HFD-210) Center for Drug Evaluation and Research (CDER) 5600 Fishers Lane, Rockville, MD 20857 (Tel) 301-827-4570 Internet at http://www.fda.gov/cder/guidance/index.htm or Office of Communication, Training and Manufacturers Assistance (HFM-40) Center for Biologics Evaluation and Research (CBER) 1401 Rockville Pike, Rockville, MD 20852-1448 (Fax) 1-888-CBERFAX or 301-827-3844 (Voice Information) 1-800-835-4709 or 301-827-1800 Internet at http://www.fda.gov/cber/guidelines.htm U.S.
    [Show full text]
  • Biocentury 8.15.16
    WEEK OF AUGUST 15, 2016 6 PRODUCT DEVELOPMENT: NO ANTIGEN LEFT BEHIND Amgen has added to its immuno-oncology arsenal with its deal for Advaxis’ pan- epitope neoantigen vaccine platform. SERVING RETURNS 9 EMERGING COMPANY PROFILE: RESTRAINING TRANSLATION BY STEVE EDELSON, SENIOR EDITOR Bantam is developing small molecule eIF4E inhibitors to treat a range of cancers, China’s Ally Bridge Group hit the investment world’s starting with B cell malignancies. radar in 2015 with its audacious move to take CRO WuXi PharmaTech Inc. private. If the firm and its partners can engineer the first fruits of that move with REGULATION: the listing of WuXi’s biologics unit in Hong Kong this 10 year, the question is what will be its next moves to ADAPTING FOR THE REAL WORLD generate outsized returns for its investors. EMA says better strategies for real-world evidence and more patient and payer involvement are necessary Ally Bridge, which has a about $1.5 billion under next steps for its adaptive pathway initiative. management across three funds and an international base of LPs, thinks its returns and continued visibility will come from a handful of public and private portfolio companies with transformative data events, the first of EBB & FLOW: 13 which should come this half. LION’S SHARE OF THE WORK Aslan’s validating event. Plus: Cutting a check The firm also says it is working on new private equity to Cleave; and Ironwood’s operating leverage. deals that will rival WuXi in terms of size and impact. Ally Bridge is keeping its private equity plans under wraps, and does not disclose names of investments in its Asia hedge fund.
    [Show full text]
  • Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Inc
    Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Pharmaceuticals International, Inc. 2012 Annual Report Valeant Gathering Momentum Company Overview Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops and markets prescription and non-prescription pharmaceutical products that make a meaningful difference in patients’ lives. Valeant’s primary focus is principally in the areas of dermatology and neurology. The Company’s growth strategy is to acquire, develop and commercialize new products through strategic partnerships, and build on the company’s strength in dermatology and neurology. Valeant plans to strategically expand its pipeline by adding new compounds or products through product or company acquisitions and will maximize its pipeline through strategic partnering to optimize its research and development assets and strengthen ongoing internal development capabilities. Valeant’s strategic markets are primarily in the United States, Canada, Central and Eastern Europe, Latin America, Australia and South East Asia. Headquartered in Montreal, Quebec, Valeant has approximately 7,000 employees worldwide. FORWARD-LOOKING Statements In addition to current and historical information, this Annual Report contains forward-looking statements, including, without limitation, statements regarding our strategy, expected future revenue, the prospects for approval of product candidates and the timing of regulatory approvals, and the growth and future development of the company, its business units and its products. Words such as “expects,” “anticipates,” “intends,” “plans,” “should,” “could,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” or “continue” or similar language identify forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties. Our actual results may differ materially from those contemplated by the forward-looking statements.
    [Show full text]
  • FDA Listing of Authorized Generics As of July 1, 2021
    FDA Listing of Authorized Generics as of July 1, 2021 Note: This list of authorized generic drugs (AGs) was created from a manual review of FDA’s database of annual reports submitted to the FDA since January 1, 1999 by sponsors of new drug applications (NDAs). Because the annual reports seldom indicate the date an AG initially entered the market, the column headed “Date Authorized Generic Entered Market” reflects the period covered by the annual report in which the AG was first reported. Subsequent marketing dates by the same firm or other firms are not included in this listing. As noted, in many cases FDA does not have information on whether the AG is still marketed and, if not still marketed, the date marketing ceased. Although attempts have been made to ensure that this list is as accurate as possible, given the volume of d ata reviewed and the possibility of database limitations or errors, users of this list are cautioned to independently verify the information on the list. We welcome comments on and suggested changes (e.g., additions and deletions) to the list, but the list may include only information that is included in an annual report. Please send suggested changes to the list, along with any supporting documentation to: [email protected] A B C D E F G H I J K L M N O P Q R S T U V X Y Z NDA Applicant Date Authorized Generic Proprietary Name Dosage Form Strength Name Entered the Market 1 ACANYA Gel 1.2% / 2.5% Bausch Health 07/2018 Americas, Inc.
    [Show full text]
  • Guidance for Industry
    Assessing User Fees Under the Prescription Drug User Fee Amendments of 2017 Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) November 2020 User Fees Assessing User Fees Under the Prescription Drug User Fee Amendments of 2017 Guidance for Industry Additional copies are available from: Office of Communications, Division of Drug Information Center for Drug Evaluation and Research Food and Drug Administration 10001 New Hampshire Ave., Hillandale Bldg., 4th Floor Silver Spring, MD 20993-0002 Phone: 855-543-3784 or 301-796-3400; Fax: 301-431-6353 Email: [email protected] https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm and/or Office of Communication, Outreach and Development Center for Biologics Evaluation and Research Food and Drug Administration 10903 New Hampshire Ave., Bldg. 71, Room 3128 Silver Spring, MD 20993-0002 Phone: 800-835-4709 or 240-402-8010 Email: [email protected] https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics/biologics- guidances U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER) November 2020 User Fees Contains Nonbinding Recommendations TABLE OF CONTENTS I. INTRODUCTION............................................................................................................
    [Show full text]
  • 11/09/2016 Provider Subsystem Healthcare and Family Services Run Time: 20:25:21 Report Id 2794D051 Page: 01
    MEDICAID SYSTEM (MMIS) ILLINOIS DEPARTMENT OF RUN DATE: 11/09/2016 PROVIDER SUBSYSTEM HEALTHCARE AND FAMILY SERVICES RUN TIME: 20:25:21 REPORT ID 2794D051 PAGE: 01 NUMERIC COMPLETE LIST OF PHARMACEUTICAL LABELERS WITH SIGNED REBATE AGREEMENTS IN EFFECT AS OF 01/01/2017 NDC NDC PREFIX LABELER NAME PREFIX LABELER NAME 00002 ELI LILLY AND COMPANY 00145 STIEFEL LABORATORIES, INC, 00003 E.R. SQUIBB & SONS, LLC. 00149 WARNER CHILCOTT PHARMACEUTICALS INC. 00004 HOFFMANN-LA ROCHE 00168 E FOUGERA AND CO. 00006 MERCK & CO., INC. 00169 NOVO NORDISK, INC. 00007 GLAXOSMITHKLINE 00172 IVAX PHARMACEUTICALS, INC. 00008 WYETH LABORATORIES 00173 GLAXOSMITHKLINE 00009 PFIZER, INC 00178 MISSION PHARMACAL COMPANY 00013 PFIZER, INC. 00182 GOLDLINE LABORATORIES, INC. 00015 MEAD JOHNSON AND COMPANY 00185 EON LABS, INC. 00023 ALLERGAN INC 00186 ASTRAZENECA LP 00024 SANOFI-AVENTIS, US LLC 00187 VALEANT PHARMACEUTICALS NORTH AMERICA 00025 PFIZER, INC. 00206 LEDERLE PIPERACILLIN 00026 BAYER HEALTHCARE LLC 00224 KONSYL PHARMACEUTICALS, INC. 00029 GLAXOSMITHKLINE 00225 B. F. ASCHER AND COMPANY, INC. 00032 SOLVAY PHARMACEUTICALS, INC. 00228 ACTAVIS ELIZABETH LLC 00037 MEDA PHARMACEUTICALS, INC. 00245 UPSHER-SMITH LABORATORIES, INC. 00039 SANOFI-AVENTIS, US LLC 00258 FOREST LABORATORIES INC 00046 AYERST LABORATORIES 00259 MERZ PHARMACEUTICALS 00049 PFIZER, INC 00264 B. BRAUN MEDICAL INC. 00051 UNIMED PHARMACEUTICALS, INC 00281 SAVAGE LABORATORIES 00052 ORGANON USA INC. 00299 GALDERMA LABORATORIES, L.P. 00053 CSL BEHRING 00300 TAP PHARMACEUTICALS INC 00054 ROXANE LABORATORIES, INC. 00310 ASTRAZENECA LP 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 00327 GUARDIAN LABS DIV UNITED-GUARDIAN INC 00062 ORTHO MCNEIL PHARMACEUTICALS 00338 BAXTER HEALTHCARE CORPORATION 00064 HEALTHPOINT, LTD. 00378 MYLAN PHARMACEUTICALS, INC.
    [Show full text]
  • Consulting the Controlled Substance Staff on Drug Abuse Potential and Labeling, Drug Scheduling, Dependence Liability and Drug Abuse Risks to the Public Health
    MANUAL OF POLICIES AND PROCEDURES CENTER FOR DRUG EVALUATION AND RESEARCH MAPP 4200.3 Rev. 1 POLICY AND PROCEDURES OFFICE OF THE CENTER DIRECTOR Consulting the Controlled Substance Staff on Drug Abuse Potential and Labeling, Drug Scheduling, Dependence Liability and Drug Abuse Risks to the Public Health Table of Contents PURPOSE ..............................................................................1 BACKGROUND ...................................................................1 POLICY .................................................................................2 PROCEDURES .....................................................................4 REFERENCES ......................................................................6 DEFINITIONS ......................................................................6 CHANGE CONTROL TABLE ............................................8 PURPOSE This MAPP establishes responsibilities and procedures in the Center for Drug Evaluation and Research (CDER) for consulting the Controlled Substance Staff (CSS) regarding the evaluation of drug abuse potential and labeling, drug scheduling, dependence liability, and drug abuse risks to the public health. This MAPP also provides a description of the role of CSS in the drug abuse assessment and the drug scheduling process within CDER. BACKGROUND CSS provides expertise to the Food and Drug Administration (FDA) Centers and CDER Offices and Divisions as part of the review process in assessing drugs for abuse potential and dependence liability. CSS fulfills
    [Show full text]
  • Prandin (Repaglinide) Tablets
    DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 020741/S-044 SUPPLEMENT APPROVAL Clinipace, Inc. Agent for Gemini Laboratories, LLC Attention: Catherine Kessler Vice President 4840 Pearl E Cir, Ste 201E Boulder, CO 80301 Dear Ms. Kessler: Please refer to your Supplemental New Drug Application (sNDA) dated and received June 29, 2018, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Prandin (repaglinide) tablets. This Prior Approval supplemental new drug application provides for revisions to the prescribing information (PI) to conform to the Pregnancy and Lactation Labeling Rule (PLLR). APPROVAL & LABELING We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text with the minor editorial revisions, listed below, and reflected in the enclosed labeling. • In the HIGHLIGHTS OF PRESCRIBING INFORMATION, the date has been revised to 1/2019. • The footer on all pages has been deleted. WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise. Reference ID: 4378916 NDA 020741/S-044 Page 2 CONTENT OF LABELING As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm.
    [Show full text]
  • (Ezogabine): a REMS Assessment Survey
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Springer - Publisher Connector Drugs - Real World Outcomes (2015) 2:335–344 DOI 10.1007/s40801-015-0042-5 SHORT COMMUNICATION Physician and Pharmacist Understanding of the Risk of Urinary Retention with Retigabine (Ezogabine): A REMS Assessment Survey 1,2 3 4 5,6 Lianna Ishihara • Melissa Beck • Sara Travis • Olusegun Akintayo • Neil Brickel5 Published online: 7 October 2015 Ó The Author(s) 2015. This article is published with open access at Springerlink.com Abstract RTG/EZG and to evaluate the effectiveness of the com- Background The Risk Evaluation and Mitigation Strategy munication plan. (REMS) for retigabine/ezogabine (RTG/EZG) required an Methods This was a US-based, cross-sectional, non-in- evaluation of the effectiveness of the communication plan terventional, observational survey, conducted from Febru- to communicate about the risks with use of RTG/EZG. ary to April 2013, of physicians who had prescribed RTG/ Objective GlaxoSmithKline conducted a survey to assess EZG in the past year, and pharmacists who had dispensed understanding of the risk of urinary retention (UR) with an antiepileptic drug within the past 3 months. Thirteen primary objective questions (five specific to UR risk) were included in the survey, which assessed healthcare profes- sionals’ (HCPs’) understanding of UR risk and symptoms of acute UR associated with RTG/EZG. The primary out- Electronic supplementary material The online version of this article (doi:10.1007/s40801-015-0042-5) contains supplementary come was the proportion of HCPs correctly answering each material, which is available to authorized users.
    [Show full text]
  • Malek V. Abbvie, Inc. Et
    Case 1:20-cv-07492-LJL Document 1 Filed 09/12/20 Page 1 of 73 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK RICHARD MALEK, on his own behalf and all others similarly situated, Civil Action No. __________ Plaintiff, v. CLASS ACTION COMPLAINT ABBVIE INC., ALLERGAN, INC., ALLERGAN SALES, LLC, ALLERGAN USA, DEMAND FOR JURY TRIAL INC., FOREST LABORATORIES, INC., FOREST LABORATORIES HOLDINGS, LTD., FOREST LABORATORIES IRELAND, LTD., and FOREST LABORATORIES, LLC, Defendants. Plaintiff Richard Malek (“Plaintiff”), on behalf of himself and all others similarly situated, brings this Class Action Complaint against AbbVie, Inc. (“AbbVie”); Allergan, Inc., Allergan Sales, LLC, and Allergan USA, Inc. (collectively, “Allergan”); and Forest Laboratories, Inc., Forest Laboratories Holdings, Ltd., Forest Laboratories, LLC, and Forest Laboratories Ireland Ltd. (collectively, “Forest”) (together with AbbVie and Allergan, “Defendants”) for Defendants’ violations of federal and state antitrust, consumer protection and unjust enrichment laws concerning the pharmaceutical drug Bystolic® (nebivolol hydrochloride) (“Bystolic”). Based upon the investigation of counsel, information and belief, and personal knowledge, Plaintiff alleges as follows: 1 CLASS ACTION COMPLAINT Case 1:20-cv-07492-LJL Document 1 Filed 09/12/20 Page 2 of 73 INTRODUCTION 1. This is an antitrust action seeking treble damages and declaratory and injunctive relief under state antitrust, consumer protection and unjust enrichment law, and federal antitrust law, as a result of Defendants’ unlawful exclusion of generic substitutes for the branded drug Bystolic. Bystolic contains the active pharmaceutical ingredient nebivolol hydrochloride or nebivolol HCl and is an important cardiovascular prescription drug used to treat high blood pressure. It is commonly referred to as a “beta blocker” or a beta-adrenergic blocking agent that reduces blood pressure.
    [Show full text]
  • Download FDA's Expedited Drug Approval Programs
    Expedited Drug Approval Programs The process for collecting evidence in support of a new drug approval involves multiple steps. Drug developers (sponsors) collect evidence during pre-clinical and clinical phases of the process and submit it to the U.S. Food and Drug Administration (FDA) for evaluation of the drug’s safety and efficacy. The next step is a final review for marketing authorization which occurs when a drug sponsor submits a New Drug Application (NDA) to FDA for small molecule drugs or a Biologics Licensing Application (BLA) for biologics. FDA follows a standard review process – which typically takes up to 10 months – to determine whether to approve the drug. Throughout this process, from drug development to post- market monitoring, there are various points in which drug sponsors and FDA interact and exchange information. The time it takes for drug development and approval varies by drug and therapeutic area and FDA review is only part of this process. In most cases, most of this time is spent by drug sponsors in the data collection phases, e.g. clinical trials. But not all approvals follow the standard review process. Drug therapies that address unmet medical needs, treat serious or life-threatening conditions, or show a significant advantage over current therapies may be eligible for one or more of FDA’s four Expedited Review Programs. These programs are designed to accelerate the approval process and make the therapies available to patients quicker if it is determined the therapies’ benefits justify their risks.1 The four Expedited Review Programs are Priority Review, Accelerated Approval, Fast Track, and Breakthrough Therapy.
    [Show full text]